Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma
Keywords:
Carcinoma, Hepatocellular, Liver Transplantation, ImmunotherapyAbstract
We report the case of a 68-year-old male with alcohol-related cirrhosis, diagnosed with hepatocellular carcinoma (HCC) noteligible for liver transplant. After immunotherapy with atezolizumab associated with bevacizumab, he underwent a successful living donor liver transplantation (LT), not showing disease evidence or graft injury, maintaining clinically and radiologically stable 14 months after surgery. This is a successful report of combined atezolizumab plus bevacizumab being used as a bridge to LT in a patient with HCC, showing an important finding in therapy in patients with unresectable tumors at diagnosis.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gabriela Azevedo Solino; Raphael Paiva Cock Paiva Cock Ferreira; Luiz Augusto Carneiro D’Albuquerque, Alberto Queiroz Farias, Lívia Zardo Trindade, Vitor Fiorin de Vasconcelos, Mariana Poltronieri Pacheco
This work is licensed under a Creative Commons Attribution 4.0 International License.